

ASX ANNOUNCEMENT

KEY ANTI-MIDKINE ANTIBODY PATENT GRANTED

- **Important antibody patent granted in Japan for anti-midkine antibodies to prevent and treat cancer, inflammatory and autoimmune diseases**
- **Broad applicability with antibodies which target the MK C-domain protected**
- **Third granted member in global patent family**

SYDNEY, 15 December 2014: Cellmid Limited (ASX: CDY) The Japanese Patent Office has granted Cellmid's patent application 2008-544071 entitled "Antibody recognising C-domain of midkine". The granted claims cover antibodies and antibody fragments, including Cellmid's lead clinical candidate CAB102, which bind to a critical functional site in the C-domain of growth factor midkine (MK).

The granted claims also cover the use of any such antibody for prevention and treatment of cancer, autoimmune disease, inflammatory disease, and any disease attributed to cell migration. Additionally, antibodies to the C-domain of MK in general are covered.

In published studies, the MK C-domain has repeatedly been shown to convey most of the disease promoting activities attributed to MK. Blocking the C-domain therefore represents a powerful potential treatment option in any MK-related disease.

"This granted patent is yet another important piece of Cellmid's comprehensive IP protection for our MK antibodies, including CAB102", said Cellmid CEO Maria Halasz. "Cellmid's patent coverage for CAB102 and other therapeutic antibodies now extends across cancer, inflammatory and autoimmune diseases, multiple sclerosis and surgical adhesion."

Granting of this patent further extends Cellmid's global protection for CAB102 and similar antibodies- equivalent patents have already been granted in Europe and Australia.

Cellmid holds the most significant intellectual property assets related to MK worldwide. Cellmid's patent portfolio currently includes 87 patents in 20 patent families, which cover use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company with lead drug candidates in immunology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only present in a disease context, and targeting midkine is not expected to harm normal healthy tissues.